Skip to main content
SpringerLink
Log in

Lipid Nanocarriers for Enhanced Delivery of Temozolomide to the Brain

  • Protocol
  • First Online:
Drug Delivery Systems

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2059))

Abstract

Brain disorders, a diverse range of conditions comprising of neurological and psychiatric conditions, are the leading cause of disability, severely affect the quality of life, and in many cases lead to mortality. The prime challenge in treatment of brain disorders is to deliver therapeutics by overcoming the blood–brain barrier (BBB), a unique anatomical and physiological barrier which restricts the passage of a number of molecules, proteins, and cells from the bloodstream. Lipid nanoparticles have emerged as promising drug delivery systems primarily because of biodegradability, low toxicity potential, and the ability to cross physiological barriers especially the BBB even without surface modifications.

In this chapter we discuss the preparation and characterization of nanostructured lipid carriers of temozolomide, a chemotherapeutic drug. Evaluation of pharmacokinetics and biodistribution of the nanocarrier system in rats revealed improved delivery of the chemotherapeutic agent to the brain with the potential of lesser side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jaul E, Barron J (2017) Age-related diseases and clinical and public health implications for the 85 years old and over population. Front Public Health 5:335

    Article  Google Scholar 

  2. Dong X (2018) Current strategies for brain drug delivery. Theranostics 8:1481–1493

    Article  CAS  Google Scholar 

  3. Banks WA (2016) From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov 15:275–292

    Article  CAS  Google Scholar 

  4. Allhenn D, Shetab Boushehri MA, Lamprecht A (2012) Drug delivery strategies for the treatment of malignant gliomas. Int J Pharm 436:299–310

    Article  CAS  Google Scholar 

  5. Wolinsky JB, Colson YL, Grinstaff MW (2012) Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. J Control Release 159:14–26

    Article  CAS  Google Scholar 

  6. Saraiva C, Praça C, Ferreira R et al (2016) Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier to treat neurodegenerative diseases. J Control Release 235:34–47

    Article  CAS  Google Scholar 

  7. Martins S, Sarmento B, Ferreira DC et al (2007) Lipid-based colloidal carriers for peptide and protein delivery - liposomes versus lipid nanoparticles. Int J Nanomedicine 2:595–607

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Sarmento B, Martins S, Ferreira D et al (2007) Oral insulin delivery by means of solid lipid nanoparticles. Int J Nanomedicine 2:743–749

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Neves AR, Lúcio M, Martins S et al (2013) Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int J Nanomedicine 8:177–187

    Article  Google Scholar 

  10. Shah B, Khunt D, Bhatt H et al (2015) Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters. Eur J Pharm Sci 78:54–66

    Article  CAS  Google Scholar 

  11. Finn JD, Smith AR, Patel MC et al (2018) A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep 22:2227–2235

    Article  CAS  Google Scholar 

  12. Apaolaza PS, del Pozo-Rodríguez A, Solinís MA et al (2016) Structural recovery of the retina in a retinoschisin-deficient mouse after gene replacement therapy by solid lipid nanoparticles. Biomaterials 90:40–49

    Article  CAS  Google Scholar 

  13. Khosa A, Reddi S, Saha RN (2018) Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother 103:598–613

    Article  CAS  Google Scholar 

  14. Gastaldi L, Battaglia L, Peira E et al (2014) Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art. Eur J Pharm Biopharm 87:433–444

    Article  CAS  Google Scholar 

  15. Wesolowski JR, Rajdev P, Mukherji SK (2010) Temozolomide (Temodar). Am J Neuroradiol 31:1383

    Article  CAS  Google Scholar 

  16. Farid RM, El-Salamouni NS, El-Kamel AH et al (2017) Lipid-based nanocarriers for ocular drug delivery. In: Andronescu E, Grumezescu AM (eds) Nanostructures for drug delivery, 1st edn. William Andrew, New York

    Google Scholar 

  17. Choulis NH (2011) Miscellaneous drugs, materials, medical devices, and techniques. In: Aronson JK (ed) Side effects of drugs annual, vol 33, 1st edn. Elsevier Science, New York

    Google Scholar 

  18. Moloughney JG, Weisleder N (2012) Poloxamer 188 (P188) as a membrane resealing reagent in biomedical applications. Recent Pat Biotechnol 6:200–211

    Article  CAS  Google Scholar 

  19. Moghimi SM, Hunter AC (2000) Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends Biotechnol 18:412–420

    Article  CAS  Google Scholar 

  20. Sinhmar GK, Shah NN, Chokshi NV et al (2018) Process, optimization and characterization of budesonide-loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease. Drug Dev Ind Pharm 44:1078–1089

    Article  CAS  Google Scholar 

  21. Rocha KAD, Krawczyk-Santos AP, Andrade LM et al (2017) Voriconazole-loaded nanostructured lipid carriers (NLC) for drug delivery in deeper regions of the nail plate. Int J Pharm 531:292–298

    Article  CAS  Google Scholar 

  22. Cirri M, Maestrini L, Maestrelli F et al (2018) Design, characterization and in vivo evaluation of nanostructured lipid carriers (NLC) as a new drug delivery system for hydrochlorothiazide oral administration in pediatric therapy. Drug Deliv 25:1910–1921

    Article  CAS  Google Scholar 

  23. Amasya G, Badilli U, Aksu B et al (2016) Quality by design case study 1: design of 5-fluorouracil loaded lipid nanoparticles by the w/o/w double emulsion-solvent evaporation method. Eur J Pharm Sci 84:92–102

    Article  CAS  Google Scholar 

  24. Schubert MA, Müller-Goymann CC (2003) Solvent injection as a new approach for manufacturing lipid nanoparticles—evaluation of the method and process parameters. Eur J Pharm Biopharm 55:125–131

    Article  CAS  Google Scholar 

  25. Oliveira DRB, Michelon M, de Figueiredo Furtado G et al (2016) β-Carotene-loaded nanostructured lipid carriers produced by solvent displacement method. Food Res Int 90:139–146

    Article  CAS  Google Scholar 

  26. Gomes GVL, Sola MR, Rochetti AL, Fukumasu H et al (2019) β-Carotene and α-tocopherol coencapsulated in nanostructured lipid carriers of murumuru (Astrocaryum murumuru) butter produced by phase inversion temperature method: characterisation, dynamic in vitro digestion and cell viability study. J Microencapsul 36:43–52

    Article  CAS  Google Scholar 

  27. Liu C-H, Wu C-T (2010) Optimization of nanostructured lipid carriers for lutein delivery. Colloids Surf A Physicochem Eng Asp 353:149–156

    Article  CAS  Google Scholar 

  28. Charcosset C, El-Harati A, Fessi H (2005) Preparation of solid lipid nanoparticles using a membrane contactor. J Control Release 108:112–120

    Article  CAS  Google Scholar 

  29. Schwarz JC, Weixelbaum A, Pagitsch E et al (2012) Nanocarriers for dermal drug delivery: influence of preparation method, carrier type and rheological properties. Int J Pharm 437:83–88

    Article  CAS  Google Scholar 

  30. Moghimi SM, Hunter AC, Andresen TL (2012) Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol 52:481–503

    Article  CAS  Google Scholar 

  31. Li S-D, Huang L (2008) Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 5:496–504

    Article  CAS  Google Scholar 

  32. Betzer O, Shilo M, Opochinsky R et al (2017) The effect of nanoparticle size on the ability to cross the blood–brain barrier: an in vivo study. Nanomedicine (Lond) 12:1533–1546

    Article  CAS  Google Scholar 

  33. Hirst TC, Vesterinen HM, Sena ES et al (2013) Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted? Br J Cancer 108:64

    Article  CAS  Google Scholar 

  34. Agency EMEA (2011) CHMP assessment report Temozolomide Sun, Procedure No. EMEA/H/C/002198. https://www.ema.europa.eu/en/documents/assessment-report/temozolomide-sun-epar-public-assessment-report_en.pdf 1–20. Accessed 21 April 2019

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Pilani, India

    Archana Khosa, Kowthavarapu V. Krishna & Sunil Kumar Dubey

  2. Birla Institute of Technology and Science, Pilani, Dubai, UAE

    Ranendra Narayan Saha

Authors
  1. Archana Khosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kowthavarapu V. Krishna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sunil Kumar Dubey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ranendra Narayan Saha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Archana Khosa .

Editor information

Editors and Affiliations

  1. Jain PharmaBiotech, Basel, Switzerland

    Kewal K. Jain

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Khosa, A., Krishna, K.V., Dubey, S.K., Saha, R.N. (2020). Lipid Nanocarriers for Enhanced Delivery of Temozolomide to the Brain. In: Jain, K. (eds) Drug Delivery Systems. Methods in Molecular Biology, vol 2059. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9798-5_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-9798-5_15

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-4939-9797-8

  • Online ISBN: 978-1-4939-9798-5

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation